Table I.
Pathway name | p-value* |
||
---|---|---|---|
Forearm | Femoral neck | Lumbar spine | |
Expression quantitative trait loci (eQTL)-based results | |||
GSE17721 PAM3CSK4 vs CPG 12H BMDM up | 0.028 | 0.038 | < 0.001 |
GSE5589 IL6 KO vs IL10 KO LPS and IL10 Stim macrophage 45 minutes up | 0.036 | 0.043 | 0.002 |
Module 195 | 0.042 | 0.011 | 0.017 |
Module 480 | 0.014 | 0.005 | 0.014 |
NABA ECM glycoproteins | 0.049 | 0.041 | 0.028 |
KEGG pathways in cancer | 0.049 | 0.038 | 0.008 |
GSE14769 unstim vs 60 minutes LPS BMDM up | 0.020 | 0.008 | 0.021 |
YTTCCNNNGGAMR unknown | 0.037 | 0.002 | 0.032 |
Darwiche papilloma risk high up | 0.040 | 0.001 | 0.038 |
GUO hex targets DN | 0.047 | 0.045 | 0.024 |
Module 427 | 0.047 | 0.001 | 0.003 |
Module 279 | 0.039 | < 0.001 | 0.003 |
Methylation quantitative trait loci (meQTL)-based results | |||
Chang cycling genes | 0.038 | 0.010 | 0.009 |
GNF2 KISS1 | 0.043 | 0.049 | 0.013 |
GNF2 MMP11 | 0.032 | 0.043 | 0.013 |
chr6q14 | 0.026 | 0.006 | 0.030 |
Kolmogorov-Smirnov running sum statistics was used and p-values were decided based on permutation3